Liangfang Shen

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 449 citations

Medicine, Oncology, Pharmacology +12

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Yu‐Pei Chen, Xu Liu, Qin Zhou et al. · The Lancet · 2021 · 234 citations

Medicine, Oncology, Pharmacology +12

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Chun Han, Sisi Ye, Chunhong Hu et al. · Frontiers in Oncology · 2021 · 67 citations · Full text

Pharmacy, Oncology, Pharmacology +15

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial

Ye Guo, Yi Luo, Qingyuan Zhang et al. · European Journal of Cancer · 2021 · 61 citations · Full text

Medicine, Oncology, Chemotherapy +8

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

Longjiang She, Huabin Hu, Mengting Liao et al. · Lung Cancer · 2019 · 59 citations

Medicine, Oncology, Pharmacoeconomics +16